ArticleBrain communications2021
Inhibition of acid sphingomyelinase increases regulatory T cells in humans.
Article in Brain communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Treatment with saturating dose of conventional anti-CD28 monoclonal antibody well tolerated in pig acute myocardial infarction model.Frontiers in immunology · 2026Article
- Psychosomatic - psychotherapeutic treatment of stress-related disorders impacts the sphingolipid metabolism towards increased sphingosine and sphingosine-1-phosphate levels.European archives of psychiatry and clinical neuroscience · 2025Article
- Risk of Acute Infections in New Users of Antihypertensive Drugs: An Observational Cohort Study.Journal of the American Heart Association · 2025Observational
- Dural Tregs driven by astrocytic IL-33 mitigate depression through the EGFR signals in mPFC neurons.Cell death and differentiation · 2025Article
- Sphingolipid biosynthesis is essential for metabolic rewiring during TScience advances · 2024Article
- Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.Frontiers in immunology · 2023Article
- Article
- Synthesis and Characterization of Ceramide-Containing Liposomes as Membrane Models for Different T Cell Subpopulations.Journal of functional biomaterials · 2022Article
- Development of Type 1 Diabetes may occur through a Type 2 Diabetes mechanism.Frontiers in endocrinology · 2022Article
- How sphingolipids affect T cells in the resolution of inflammation.Frontiers in pharmacology · 2022Review
- Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective.International journal of molecular sciences · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic deficiency for acid sphingomyelinase or its pharmacological inhibition has been shown to increase Foxp3
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.